N
Niall P. Murphy
Researcher at Semel Institute for Neuroscience and Human Behavior
Publications - 69
Citations - 3198
Niall P. Murphy is an academic researcher from Semel Institute for Neuroscience and Human Behavior. The author has contributed to research in topics: Nociceptin receptor & Dopamine. The author has an hindex of 28, co-authored 66 publications receiving 2881 citations. Previous affiliations of Niall P. Murphy include University of California, Los Angeles & Babraham Institute.
Papers
More filters
Journal ArticleDOI
Exogenous and evoked oxytocin restores social behavior in the Cntnap2 mouse model of autism
Olga Peñagarikano,Olga Peñagarikano,Maria T. Lazaro,Xiao-Hong Lu,Aaron Gordon,Hongmei Dong,Hoa A. Lam,Elior Peles,Nigel T. Maidment,Niall P. Murphy,X. William Yang,Peyman Golshani,Peyman Golshani,Daniel H. Geschwind,Daniel H. Geschwind +14 more
TL;DR: Dysregulation of the oxytocin system in Cntnap2 knockout mice shows that there may be critical developmental windows for optimal treatment to rectify this deficit, and it is found that giving young CDFE mice multiple doses of Oxytocin just after birth produces a long-lasting improvement in oxytocIn brain levels and sociability.
Journal ArticleDOI
Aldehyde dehydrogenase inhibition as a pathogenic mechanism in Parkinson disease
Arthur G. Fitzmaurice,Shannon L. Rhodes,Aaron Lulla,Niall P. Murphy,Hoa A. Lam,Kelley C. O’Donnell,Lisa M. Barnhill,John E. Casida,Myles Cockburn,Alvaro Sagasti,Mark Stahl,Nigel T. Maidment,Beate Ritz,Jeff M. Bronstein,Jeff M. Bronstein +14 more
TL;DR: It is proposed that benomyl, via its bioactivated thiocarbamate sulfoxide metabolite, inhibits aldehyde dehydrogenase (ALDH), leading to accumulation of the reactive dopamine metabolite 3,4-dihydroxyphenylacetaldehyde (DOPAL), preferential degeneration of dopamine neurons, and development of PD.
Journal ArticleDOI
Intracerebroventricular orphanin FQ/Nociceptin supresses dopamine release in the nucleus accumbens of anaesthetized rats
TL;DR: It is reported that orphanin FQ suppresses dopamine release in the nucleus accumbens in a dose-dependent manner, providing the first neurochemical evidence for a modulatory role of this recently described peptide in the CNS.
Journal ArticleDOI
Orphanin FQ/nociceptin blocks acquisition of morphine place preference.
TL;DR: Orphanin FQ/nociceptin (OFQ/N) suppresses the activity of the dopaminergic mesolimbic reward pathway yet reportedly fails to produce conditioned place aversion or preference, and was sought to determine if this peptide could attenuate the development of morphine place preference.
Journal ArticleDOI
Orphanin FQ/Nociceptin Modulation of Mesolimbic Dopamine Transmission Determined by Microdialysis
TL;DR: Data indicate that orphanin FQ decreases dopamine transmission in the nucleus accumbens by inhibiting dopamine neuronal activity in the ventral tegmental area through a mechanism that may involve an increased overflow of GABA.